Clinical Trial

Flow Cytometric Immune Monitoring of B. Afzelii-Specific T Lymphocytes

Study acronym: LyTLymICS-AIM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Lyme borreliosis diagnosis currently relies on clinical assessment and detection of Borrelia-specific antibodies. However, serology does not allow reliable assessment of active infection. Evaluation of the cellular immune response through Borrelia-specific T lymphocyte monitoring may provide complementary diagnostic and prognostic information. This study aims to assess Borrelia afzelii-specific T-cell responses using multiparameter flow cytometry after stimulation with standardized peptide pools. This approach enables the characterization of CD4+ and CD8+ T cells, including polyfunctional immune responses. The diagnostic and prognostic value of this immunomonitoring strategy will be evaluated in patients with acrodermatitis chronica atrophicans, a late manifestation of Lyme borreliosis associated with B. afzelii.
Trial Details
NCT Number NCT07703787
Lead Sponsor University Hospital, Strasbourg, France
Conditions Lyme Borreliosis, Lyme Disease
Enrollment 20 participants
Start Date 2026-09
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-14